Akebia Therapeutics, Inc. - Common Stock (AKBA)
CUSIP: 00972D105
Q3 2024 13F Holders as of 30 Sep 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 263,222,327
- Total 13F shares
- 59,433,206
- Share change
- -479,282
- Total reported value
- $78,446,645
- Put/Call ratio
- 62%
- Price per share
- $1.32
- Number of holders
- 113
- Value change
- +$886,944
- Number of buys
- 54
- Number of sells
- 39
Quarterly Holders Quick Answers
What is CUSIP 00972D105?
CUSIP 00972D105 identifies AKBA - Akebia Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 00972D105:
Top shareholders of AKBA - Akebia Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock Finance, Inc. |
13F
|
Company |
4.4%
|
11,638,484
|
$11,871,253 | — | 30 Jun 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.5%
|
9,276,263
|
$9,461,789 | — | 30 Jun 2024 | |
| Alerce Investment Management, L.P. |
13F
|
Company |
2.2%
|
5,747,906
|
$5,862,864 | — | 30 Jun 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.7%
|
4,536,292
|
$4,627,473 | — | 30 Jun 2024 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
1.5%
|
4,063,383
|
$4,143,000 | — | 30 Jun 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.5%
|
3,914,800
|
$3,993,096 | — | 30 Jun 2024 | |
| STATE STREET CORP |
13F
|
Company |
1%
|
2,747,240
|
$2,802,185 | — | 30 Jun 2024 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.8%
|
2,094,733
|
$2,136,628 | — | 30 Jun 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.66%
|
1,744,616
|
$1,779,508 | — | 30 Jun 2024 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.4%
|
1,046,059
|
$1,066,980 | — | 30 Jun 2024 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.33%
|
865,252
|
$882,557 | — | 30 Jun 2024 | |
| Ellen Snow |
3/4/5
|
SVP, CFO and Treasurer |
—
mixed-class rows
|
743,300
mixed-class rows
|
$872,424 | — | 31 Jan 2024 | |
| Michel Dahan |
3/4/5
|
SVP, Chief Operating Officer |
—
mixed-class rows
|
896,092
mixed-class rows
|
$846,836 | — | 13 May 2024 | |
| Nicole R. Hadas |
3/4/5
|
SVP, Chief Legal Officer |
—
mixed-class rows
|
875,243
mixed-class rows
|
$820,566 | — | 13 May 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.29%
|
763,332
|
$778,599 | — | 30 Jun 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.23%
|
604,551
|
$616,642 | — | 30 Jun 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.22%
|
570,974
|
$582,393 | — | 30 Jun 2024 | |
| FMR LLC |
13F
|
Company |
0.21%
|
541,509
|
$552,340 | — | 30 Jun 2024 | |
| David A. Spellman |
3/4/5
|
SVP, CFO and Treasurer |
—
class O/S missing
|
446,483
|
$546,004 | — | 16 May 2023 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.17%
|
436,886
|
$445,624 | — | 30 Jun 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.14%
|
380,535
|
$388,146 | — | 30 Jun 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.13%
|
348,918
|
$355,897 | — | 30 Jun 2024 | |
| Violetta Cotreau |
3/4/5
|
SVP, Chief Accounting Officer |
—
class O/S missing
|
219,954
|
$268,982 | — | 12 May 2022 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.09%
|
248,813
|
$253,789 | — | 30 Jun 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.09%
|
247,069
|
$252,010 | — | 30 Jun 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.09%
|
247,060
|
$251,993 | — | 30 Jun 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.09%
|
227,144
|
$231,686 | — | 30 Jun 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.08%
|
214,669
|
$218,962 | — | 30 Jun 2024 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.08%
|
211,647
|
$215,880 | — | 30 Jun 2024 | |
| Dell J. Faulkingham |
3/4/5
|
SVP, CCO |
—
mixed-class rows
|
373,841
mixed-class rows
|
$212,590 | — | 28 Feb 2022 | |
| SAPIENT CAPITAL LLC |
13F
|
Company |
0.08%
|
200,000
|
$204,000 | — | 30 Jun 2024 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.07%
|
175,802
|
$179,317 | — | 30 Jun 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.06%
|
151,849
|
$154,886 | — | 30 Jun 2024 | |
| UBS Group AG |
13F
|
Company |
0.05%
|
142,828
|
$145,684 | — | 30 Jun 2024 | |
| TUDOR INVESTMENT CORP ET AL |
13F
|
Company |
0.05%
|
142,274
|
$145,119 | — | 30 Jun 2024 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.05%
|
129,896
|
$132,494 | — | 30 Jun 2024 | |
| Invesco Ltd. |
13F
|
Company |
0.05%
|
129,786
|
$132,382 | — | 30 Jun 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.05%
|
126,648
|
$130,000 | — | 30 Jun 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.05%
|
126,494
|
$129,024 | — | 30 Jun 2024 | |
| Corebridge Financial, Inc. |
13F
|
Company |
0.04%
|
111,914
|
$115,271 | — | 30 Jun 2024 | |
| Creative Planning |
13F
|
Company |
0.04%
|
110,690
|
$112,904 | — | 30 Jun 2024 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
0.04%
|
101,100
|
$103,122 | — | 30 Jun 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.04%
|
96,099
|
$98,021 | — | 30 Jun 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.03%
|
88,884
|
$90,662 | — | 30 Jun 2024 | |
| TD Waterhouse Canada Inc. |
13F
|
Company |
0.03%
|
90,553
|
$90,248 | — | 30 Jun 2024 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.03%
|
88,350
|
$89,000 | — | 30 Jun 2024 | |
| Orchard Capital Management, LLC |
13F
|
Company |
0.03%
|
86,826
|
$88,563 | — | 30 Jun 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.03%
|
77,640
|
$79,193 | — | 30 Jun 2024 | |
| Virtu Financial LLC |
13F
|
Company |
0.03%
|
75,079
|
$77,000 | — | 30 Jun 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.03%
|
72,603
|
$74,055 | — | 30 Jun 2024 |
Institutional Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q3 2024
As of 30 Sep 2024,
Akebia Therapeutics, Inc. - Common Stock (AKBA) was held by
113 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
59,433,206 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, Alerce Investment Management, L.P., GEODE CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP, JACOBS LEVY EQUITY MANAGEMENT, INC, NORTHERN TRUST CORP, Qube Research & Technologies Ltd, and MORGAN STANLEY.
This page lists
113
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
100
Q3 2024 holders
113
Holder diff
13
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 Value $ | Q3 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.